Isepamicin versus amikacin for the treatment of acute pyelonephritis in children

In this study we compared the efficacy and safety of isepamicin versus amik acin at a dose of 7.5 mg/kg i.v. q12h for 10-14 days in children with pyelo nephritis. Sixteen children were enrolled in the study; ten received isepam icin and six amikacin. Urine cultures grew Escherichia coil in all patients . All patients were treated successfully with either isepamicin or amikacin . Clinical and bacteriological response rates were 100% for both groups. No adverse events occurred. Peak serum levels ranged from 9.05 to 30.70 mg/l (median: 16.165) and from 12.20 to 25.90 mg/l (median: 19.05) for isepamici n and amikacin, respectively. Trough serum levels ranged from 0.11 to 3.20 mg/l (median: 0.75) and from 0.1 to 2.1 mg/l (median: 0.655), respectively. Isepamicin was shown to be as effective and safe as amikacin in the treatm ent of children with pyelonephritis and might prove an advantageous alterna tive in areas with high incidence of resistance to other aminoglycosides. ( C) 2000 Elsevier Science B.V. and International Society of Chemotherapy. Al l rights reserved.